trending Market Intelligence /marketintelligence/en/news-insights/trending/j_fkofCAim2utdSTSg7umQ2 content esgSubNav
In This List

Deciphera's gastrointestinal tumor drug secures EMA orphan drug designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Deciphera's gastrointestinal tumor drug secures EMA orphan drug designation

Deciphera Pharmaceuticals, Inc.'s gastrointestinal stromal tumor treatment DCC-2618 secured an orphan drug designation from the European Medicines Agency.

Gastrointestinal stromal tumors are uncommon tumors that start in special cells in the wall of the gastrointestinal tract, also known as the digestive tract.

The treatment has previously received an orphan drug designation from the U.S. Food and Drug Administration.

An orphan drug designation from the EMA allows a pharmaceutical company to benefit from incentives from the EU to develop a medicine for a rare disease.

DCC-2618 is in a phase 1 clinical trial.